

Indication	Gynae cancer: epithelial uterine, cervical, vulval, vaginal and ovarian. Head and Neck: Salivary / parotid gland cancer Upper GI: Adenocarcinoma of the lower Oesophagus or Type 1 Or 2 Gastro-Oesophageal Junction Cancer.
Treatment Intent	Palliative: Ovarian, cervical, vulval, vaginal, Epithelial uterine and salivary / parotid gland Adjuvant: Epithelial uterine and ovarian Neo-adjuvant: Epithelial uterine, ovarian and lower oesophagus or type 1 or 2 GO junction
Frequency and number of cycles	Repeat every 21 days Gynae: 6-8 cycles (stop at 6 for palliative treatment), 4-6 cycles for adjuvant treatment of epithelial uterine cancer Head and Neck up to 6 cycles UGI: 1-2 cycles followed by weekly carboplatin and paclitaxel with radiotherapy (UGI-036).
Monitoring Parameters pre-treatment	<ul style="list-style-type: none"> • EDTA/DTPA should be used to measure GFR prior to cycle 1. C+G may be used to estimate CrCl if there is a delay in obtaining EDTA result. • AUC 5 should be used where an EDTA result is available, otherwise if GFR is estimated (C+G) AUC 6 may be used at clinician discretion. • Monitor U+Es, LFTs and FBC at each cycle. If CrCl falls by >25%repeat EDTA and d/w consultant. • If neuts <1.5 and/or PLT <100 defer treatment by one week. Consider dose reduction on subsequent cycles • Hepatic impairment: <ul style="list-style-type: none"> ○ Carboplatin: No dose adjustment required. ○ Paclitaxel: If bilirubin < 1.25 x ULN and transaminase < 10 x ULN, dose at full dose. Otherwise consider dose reduction, not recommended in severe hepatic impairment. • Renal impairment: <ul style="list-style-type: none"> ○ Carboplatin: stop if CrCl<30ml/min ○ Paclitaxel: no dose reduction necessary. • Infusion-related reactions: <ul style="list-style-type: none"> ○ Paclitaxel: Patients developing hypersensitivity reactions to paclitaxel may be rechallenged with full dose paclitaxel following prophylactic medication (e.g. famotidine 40mg po given 4 hours prior to treatment plus hydrocortisone 100mg iv and chlorphenamine 10mg iv 30 minutes prior to treatment, then give paclitaxel over 3-6 hours (i.e. starting at over 6 hours and gradually increase rate if possible). ○ Carboplatin: Mild/moderate reactions (grade 1-2): If symptoms resolve after treatment with hydrocortisone and chlorphenamine, the infusion may be restarted at 50% rate for 30 mins, then, if no further reaction, increase to 100% rate. If symptoms do not resolve after treatment with hydrocortisone and chlorphenamine, do not restart the infusion. At consultant's discretion, patients may be rechallenged at a later date with additional prophylaxis. In the event of further reaction (grade 1-3), stop infusion and consider alternative treatment. Severe (grade 3): Do not restart infusion. Consider alternative treatment. Anaphylaxis (grade 4): Follow anaphylaxis protocol. Discontinue permanently and consider alternative treatment. • Dose Modification: <ul style="list-style-type: none"> ○ Paclitaxel: Dose reduce Paclitaxel by 20% in the event of >/= grade 2 neuropathy and consider delay until recovery to </= grade 1.

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V1	Written by	M.Archer
Supersedes version	GYN-002 V6	Checked by	C.Waters O. Adebayo
Date	22.07.2022	Authorising consultant (usually NOG Chair)	T.Sevitt. J.Waters. K.Nathan

	<ul style="list-style-type: none"> ○ Consider omitting paclitaxel in event of recurrent grade \geq 3 neuropathy OR recurrent or persistent \geq grade 2 neuropathy following a dose reduction. ○ Dose reduction of carboplatin and paclitaxel should be considered if any other grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to \leq grade 1. ● Common drug interactions (for comprehensive list refer to BNF/SPC): <ul style="list-style-type: none"> ○ Paclitaxel: Caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole, erythromycin, fluoxetine, clopidogrel, cimetidine, ritonavir and nelfinavir); toxicity may be increased. CYP2C8 or CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) may reduce efficacy. ○ Carboplatin: Caution with other nephrotoxic drugs.
References	KMCC proforma GYN-002 v6 and HNT-005 V2 SPC accessed online 27.07.21

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V1	Written by	M.Archer
Supersedes version	GYN-002 V6	Checked by	C.Waters O. Adebayo
Date	22.07.2022	Authorising consultant (usually NOG Chair)	T.Sevitt. J.Waters. K.Nathan

Repeat every 21 days

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 1	Give pre-meds 30 minutes prior to paclitaxel				
	Dexamethasone	16mg	IV	Bolus	
	Chlorphenamine	10mg	IV	Slow bolus	Through the side of a fast running Sodium Chloride 0.9% intravenous infusion.
	Ondansetron	<75yrs 16mg ≥75yrs 8mg	IV	15 min	Sodium chloride 0.9% 50ml
	PACLITAXEL	175mg/m²	IV	3 hrs	In 500ml Sodium Chloride 0.9% (if dose <150mg in 250ml Sodium Chloride 0.9%) Use non-PVC bag and non-PVC administration set via in-line 0.22 microns filter. Flush with sodium chloride 0.9%
	CARBOPLATIN Dose = (GFR + 25) x AUC	AUC 5 (dose capped at 790mg on epx system)	IV	30 mins	Glucose 5% 500ml In clinical practice the dose is usually capped at either 700mg OR for a maximum calculated dose of GFR 125ml/min
TTO	Drug	Dose	Route	Directions	
Day 1	Dexamethasone	6mg	PO	OM for 3 days	
	Metoclopramide	10mg	PO	Take 10mg THREE times a day for 3 days then take 10mg up to THREE times a day when required (Maximum of 30mg per day). Do not take for more than 5 days continuously.	

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V1	Written by	M.Archer	
Supersedes version	GYN-002 V6	Checked by	C.Waters O. Adebayo	
Date	22.07.2022	Authorising consultant (usually NOG Chair)	T.Sevitt. J.Waters. K.Nathan	